AI Summary

The U.S. Food and Drug Administration approved Merck’s Idvynso, a once‑daily single‑tablet regimen for adults with HIV‑1 who are virologically suppressed (HIV‑1 RNA <50 copies/mL). The tablet combines 100 mg doravirine and 0.25 mg islatravir. It is intended to replace a current antiretroviral regimen in patients on a stable therapy with no history of virologic treatment failure and no known resistance substitutions to doravirine.

AI summaries can be wrong sometimes—always verify important details using the source article.